Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?

Authors

  • Daniel H. Solomon,

    Corresponding author
    1. Brigham and Women's Hospital, Boston, Massachusetts
    • Division of Rheumatology and Division of Pharmacoepidemiology, Brigham and Women's Hospital, 75 Francis Street, PBB-B3, Boston, MA 02115. E-mail: dsolomon@partners.org

    Search for more papers by this author
    • Dr. Solomon receives royalties from UpToDate. He has received support through research grants to Brigham and Women's Hospital from Amgen, Lilly, Pfizer, and the Consortium of Rheumatology Researchers of North America (CORRONA) registry and has served in unpaid roles in trials funded by Pfizer, Novartis, Lilly, and Bristol-Myers Squibb.

  • Asaf Bitton,

    1. Brigham and Women's Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Jeffrey N. Katz,

    1. Brigham and Women's Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Helga Radner,

    1. Medical University of Vienna, Vienna, Austria
    2. Brigham and Women's Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Erika M. Brown,

    1. Brigham and Women's Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Liana Fraenkel

    1. Yale School of Medicine, New Haven, Connecticut, and VA Connecticut Healthcare System, West Haven, Connecticut
    Search for more papers by this author

Ancillary